1.
Med Monatsschr Pharm
; 31(5): 184-5, 2008 May.
Artículo
en Alemán
| MEDLINE
| ID: mdl-18552075
RESUMEN
The indication for HMG-CoA-reductase-inhibitors (CSE inhibitors, "statins") for primary prevention of atherosclerosis requires a careful risk/benefit calculation. For this, the PROCAM and SCORE risk scores offer validated, hands on decision support tools. In patients with manifest atherosclerosis and diabetes mellitus statins are indicated regardless of the serum cholesterol level.
Asunto(s)
Aterosclerosis/tratamiento farmacológico , Complicaciones de la Diabetes/tratamiento farmacológico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Colesterol/sangre , Humanos , Hipercolesterolemia/complicaciones
2.
Infect Immun
; 74(10): 6006-10, 2006 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-16988280
RESUMEN
Mutation of tryptophan-101 in Clostridium difficile toxin A, a 308-kDa glucosyltransferase, resulted in a 50-fold-reduced cytopathic activity in cell culture experiments. The mutant toxin A was characterized and applied to distinguish between glucosyltransferase-dependent and -independent effects with respect to RhoB up-regulation as a cellular stress response.